Suya Wang

Suya Wang is a Scientist II at Fractyl Health since October 2022, focusing on the development and evaluation of AAV-based gene therapies and establishing high-throughput screening pipelines. Prior to this role, Suya Wang served as an Instructor and Postdoctoral Researcher at Boston Children's Hospital, where contributions included characterizing murine models of Barth Syndrome and leading AAV gene therapy development. Additional experience includes an instructor position at Harvard Medical School and a Graduate Research Assistant role at The University of Kansas, where experimental protocols were designed and optimized. Suya Wang's academic background includes a PhD in Pharmacology and Toxicology from The University of Kansas and a BS in Pharmacy from China Pharmaceutical University.